K. pneumonia has been reported as a threat to human health due to the emergence of multidrug resistant isolates. This research was aimed at identifying the resistance rates of K. Pneumoniae to fluoroquinolones in 2021, its European age distribution and its resistance rates compared to carbapenems. The potential for K. Pneumoniae to increase or reduce susceptibility to fluoroquinolones in the next decade was determined by examining the resistance profile in 4 European countries for 16 years. Results observed highlighted that K. Pneumoniae isolates in Europe were more susceptible to Carbapenems compared to fluoroquinolones in the year 2021. The research also identified an over 50% resistance of K. Pneumoniae Europeans isolate for ages 19 and higher. The about 2 fold resistance increase observed to fluoroquinolones over16 years pose a high therapeutic threat to Europeans over the age of 19 over the next decade as K. Pneumoniae has shown tendencies to increase in their resistance rates. Thus European Health organisations need to create policies to curb the use of fluoroquinolones in the treatment of K. Pneumoniae infections and preserve administration to rare cases to limit rate of resistance development.
IRE Journals:
Olufunmilayo A. Mohammed , Peter Uaboi-Egbenni , Perezimor Etifa
"Comparative Analysis: Resistance of Klebsiella Pneumoniae to Fluoroquinolone and Carbapenem in European Countries" Iconic Research And Engineering Journals Volume 9 Issue 1 2025 Page 1852-1857
IEEE:
Olufunmilayo A. Mohammed , Peter Uaboi-Egbenni , Perezimor Etifa
"Comparative Analysis: Resistance of Klebsiella Pneumoniae to Fluoroquinolone and Carbapenem in European Countries" Iconic Research And Engineering Journals, 9(1)